Urothelial Carcinoma
📧 Sign up to get email alerts when something new happens for Urothelial Carcinoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-04-03FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)
FDA approved a supplemental application for PADCEV (enfortumab vedotin) submitted by Seagen Inc. This document communicates the FDA's approv…
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer [Phase 2]
Phase 2 single-arm study of bempegaldesleukin (NKTR-214) with nivolumab in cisplatin-ineligible, locally advanced or metastatic urothelial c…
-
CLINICAL_TRIALS trial_result · 2023-03-24Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) [Phase 2]
Phase 2 results update evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with urothelial carcinoma (FIGHT-201). Res…
-
FDA approval · 2023-03-20FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for Balversa (erdafitinib) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC [Phase 2]
Phase 2 clinical trial evaluating safety and efficacy of AZD4547 in combination with tislelizumab for urothelial carcinoma is in progress wi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-14Clinical Trial Update: A Study of ICP-192 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
A clinical trial update for ICP-192 in advanced solid tumors and urothelial carcinoma (Phase 1/2). Status is unknown.
-
CLINICAL_TRIALS trial_result · 2023-03-13Clinical Trial Update: A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating NKTR-214 in combination with nivolumab and other anti-cancer therapies in select advanced solid tumors completed …
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors [Phase 1, Phase 2]
A Phase I/II study investigating regorafenib in combination with avelumab in various solid tumors, spanning Phase 1 and Phase 2 cohorts.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors [Phase 1]
Phase 1 trial update on an arginase-1 peptide vaccine in patients with metastatic solid tumors, including non-small cell lung cancer and uro…
-
FDA approval · 2023-01-11FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
FDA approves a supplemental application for BALVERSA (erdafitinib) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2022-11-30Clinical Trial Update: Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma [Phase 2]
Phase 2 clinical trial evaluating pembrolizumab plus nab-paclitaxel in metastatic urothelial carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-30Clinical Trial Update: Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma [Phase 2]
Phase 2 trial evaluating perioperative tislelizumab with nab-paclitaxel for muscle-invasive urothelial bladder cancer shows an ongoing study…
-
CLINICAL_TRIALS trial_result · 2022-11-25Clinical Trial Update: Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) [Phase 2]
Phase 2 trial evaluating IPI-549 in combination with nivolumab for advanced urothelial carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-11-02Clinical Trial Update: Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma [Phase 2]
Phase 2 trial evaluating mitomycin C during nephroureterectomy for urothelial carcinoma; the study is completed with results posted.
-
FDA approval · 2022-10-28FDA Approved: PADCEV EJFV — Supplemental Application (SEAGEN INC.)
FDA approved a supplemental application for PADCEV EJFV (enfortumab vedotin) by Seagen.
-
CLINICAL_TRIALS trial_result · 2022-10-26Clinical Trial Update: Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors [Phase 1, Phase 2]
Phase 1/2 trial evaluating aibrutinib combination therapy in selected gastrointestinal and genitourinary tumors has completed with results p…
-
CLINICAL_TRIALS trial_result · 2022-09-30Clinical Trial Update: Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer [Phase 2]
Phase 2 trial updating pembrolizumab as maintenance therapy after initial chemotherapy in metastatic bladder cancer; study completed with re…
-
CLINICAL_TRIALS trial_result · 2022-08-03Clinical Trial Update: Biological Effect of Vitamin D in Patients With Urothelial Carcinoma [Phase 4]
Phase 4 clinical trial evaluating the biological effect of vitamin D in patients with urothelial carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2022-07-25Clinical Trial Update: A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer [Phase 2]
Phase 2b study of UGN-102 for low-grade, intermediate-risk non-muscle-invasive bladder cancer has completed with results posted in 2022.
-
CLINICAL_TRIALS trial_result · 2022-07-01Clinical Trial Update: Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors [Phase 2]
Phase 2 trial evaluating famitinib plus anti-PD1 therapy for advanced renal cell carcinoma, urothelial carcinoma, and gynecologic cancers su…
-
CLINICAL_TRIALS trial_result · 2022-06-13Clinical Trial Update: Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study [Phase 2]
A Phase 2 multicenter trial evaluating perioperative tislelizumab combined with nab-paclitaxel for muscle-invasive urothelial bladder cancer…
-
CLINICAL_TRIALS trial_result · 2022-05-25Clinical Trial Update: Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) [Phase 2]
A Phase 2 trial (FIGHT-205) comparing Pemigatinib + Pembrolizumab vs Pemigatinib alone vs standard of care in metastatic or unresectable uro…
-
CLINICAL_TRIALS trial_result · 2022-05-23Clinical Trial Update: Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy [Phase 2]
Phase 2 trial update evaluating maintenance niraparib in advanced urothelial cancer after first-line platinum-based chemotherapy has complet…
-
FDA approval · 2022-04-27FDA Approved: BALVERSA — Supplemental Application (Janssen Products LP)
The FDA approved a supplemental application for BALVERSA (erdafitinib) submitted by Janssen Products LP.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence [Phase 2]
Phase 2 clinical trial update evaluating intravesical gemcitabine to prevent recurrence in urothelial carcinoma.